SELECT FROM MENU

Therapy Area
Drug Classes

       Disease Area

All Sessions

All Sessions

All Sessions

Resectable NSCLC

All Sessions

Metastatic NSCLC

All Sessions

SCLC

All Sessions

Biomarkers

       Drug Class

Targeted Therapies

Targeted Therapies

Immuno-therapies

Immuno-therapies

Antibody-Drug Conjugates

Antibody-Drug Conjugates

Antonio Passaro

Antonio Passaro

European Institute of Oncology (IEO), Milan

Dr. Antonio Passaro is a thoracic medical oncologist in the Division of Thoracic Oncology at the European Institute of Oncology (IEO) in Milan, Italy. His research focuses on EGFR-mutant and oncogene-addicted non-small cell lung cancer, resistance mechanisms to targeted therapy, and antibody-drug conjugates, with involvement in trials such as TROPION-Lung05 and consensus work on EGFR-mutant NSCLC. He is an ESMO faculty member for lung and other thoracic tumours and served as a scientific committee co-chair of the European Lung Cancer Congress (ELCC) 2026. He is a frequent speaker at major international thoracic oncology congresses.

Connect

Antonio Passaro

Featured in

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates